X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.fiercepharma.com/manufacturing/johnson-johnson-legend-expand-manufacturing-deal-novartis-commercial-production
https://www.prnewswire.com/news-releases/neoimmunetech-to-present-first-data-on-nt-i7-efineptakin-alfa-in-combination-with-car-t-tisagenlecleucel-at-2022-ash-annual-meeting-301668788.html
https://www.globenewswire.com/news-release/2022/06/12/2460797/0/en/Novartis-five-year-Kymriah-data-show-durable-remission-and-long-term-survival-maintained-in-children-and-young-adults-with-advanced-B-cell-ALL.html
https://www.prnewswire.com/news-releases/fda-approves-novartis-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-301556984.html
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma
https://www.fiercepharma.com/pharma/novartis-has-idea-why-kymriah-failed-lymphoma-shifts-focus-to-next-gen-car-t
https://www.livemint.com/companies/news/blackstone-to-invest-up-to-250-million-in-autolus-therapeutics-of-uk-11636374227693.html
https://www.pharmatimes.com/news/priority_review_for_novartis_car-t_cell_therapy_kymriah_1382303
https://www.biospace.com/article/crispr-therapeutics-announces-promising-data-for-its-car-t-cancer-therapy/?s=71
https://endpts.com/novartis-car-t-fails-to-help-a-vulnerable-group-of-nhl-patients-quashing-hope-of-moving-up-lines-of-treatment/
https://endpts.com/hhs-inspector-general-signs-off-on-novartis-paying-for-pricey-kymriah/
https://www.biospectrumasia.com/news/98/17738/singapore-approves-first-commercial-car-t-therapy-by-novartis.html
https://www.novartis.com.sg/news/media-releases/novartis-receives-approval-kymriah-tisagenlecleucel-health-sciences-authority
https://endpts.com/5-years-later-car-t-pioneer-kymriah-offers-jaw-dropping-evidence-of-durable-remissions-even-as-it-still-proves-a-tough-sell/
https://www.fiercepharma.com/pharma/ash-novartis-makes-its-kymriah-case-follicular-lymphoma-but-another-gilead-showdown-awaits
https://www.fiercebiotech.com/research/ash-crispr-edited-car-t-cells-show-enhanced-activation-against-leukemia-mice
https://www.contractpharma.com/contents/view_breaking-news/2020-11-03/novartis-expands-kymriah-manufacturing-footprint/
https://www.fiercepharma.com/manufacturing/novartis-looks-to-hurdle-manufacturing-crunch-for-car-t-therapy-kymriah-first-asian
https://www.fiercepharma.com/manufacturing/novartis-looks-to-hurdle-manufacturing-crunch-for-car-t-therapy-kymriah-first-asian
https://endpts.com/esmo20-autolus-provides-glimpse-of-next-generation-car-t-program-showing-early-positive-safety-data/
https://www.fiercebiotech.com/biotech/from-natural-killer-cells-to-off-shelf-car-ts-biopharma-targets-cancer-next-gen-cell
https://www.fiercebiotech.com/research/virus-combo-makes-solid-tumors-vulnerable-to-car-t-attack-mice
https://www.fiercepharma.com/marketing/novartis-eyes-3rd-kymriah-indication-follicular-lymphoma-trial-win
https://endpts.com/fda-oks-morphosys-incytes-potential-blockbuster-car-t-alternative/
https://www.clinicalomics.com/sponsored/navigating-complexity-in-oncology-cell-and-gene-therapy-clinical-trials/
http://www.pmlive.com/pharma_news/asco_momentum_gathers_behind_next_wave_of_car-t_therapies_1341334
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-follicular-lymphoma
https://www.prnewswire.com/news-releases/novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-in-follicular-lymphoma-301044971.html
https://www.nasdaq.com/articles/novartis-kymriah-gets-fda-rmat-designation-in-follicular-lymphoma-2020-04-22
https://www.biopharmadive.com/news/bristol-myers-liso-cel-car-t-speedy-fda-review/572273/
http://endpts.com/kymriah-pioneer-carl-june-is-back-with-first-evidence-for-crispr-use-in-cancer/
https://www.fiercepharma.com/marketing/not-kickback-hhs-allows-novartis-kymriah-travel-assistance-program-for-public-patients
https://www.fiercepharma.com/marketing/not-kickback-hhs-allows-novartis-kymriah-travel-assistance-program-for-public-patients
https://www.medecinsdumonde.org/en/news/nos-combats/2019/12/16/novartis-withdraws-abusive-patent-over-priced-cancer-medication
https://www.biopharmadive.com/news/novartis-kymriah-car-t-manufacturing-difficulties-cell-viability/568830/
https://www.fiercepharma.com/manufacturing/novartis-new-cell-therapy-facility-could-ease-manufacturing-squeeze-for-car-t-med
https://www.reuters.com/article/us-novartis-swiss-factory/novartiss-90-million-swiss-factory-to-help-solve-cell-therapy-bottleneck-idUSKBN1Y214Y
https://www.fiercebiotech.com/biotech/celgene-posts-pivotal-car-t-data-ahead-fda-filing
https://www.contractpharma.com/contents/view_breaking-news/2019-10-23/aldevron-nature-technology-team-up-for-gene-therapy-manufacturing/
https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level
https://www.fiercebiotech.com/research/car-t-a-new-target-could-address-cancer-relapses
https://www.fiercebiotech.com/research/penn-team-repurposes-car-t-cancer-tech-to-treat-heart-disease
https://endpts.com/penn-team-adapts-car-t-tech-reengineering-mouse-cells-to-treat-cardiac-fibros
https://www.biopharmadive.com/news/immatics-celgene-deal-pipeline-t-cell-therapy-cancer/561853/
Market Place
Share 
